Critical Analysis: Intra-Cellular Therapies, Inc. v. Controller of Patents (2026:DHC:5394) C.A.(COMM.IPD-PAT) 24/2023 | Delhi High Court | Decided: 06.07.2026 I. Doctrinal Analysis: Novelty and the "Coverage vs. Disclosure" Question A. The genus-species anticipation problem The core novelty dispute was a classic Markush-genus-versus-species-selection issue. The appellant argued that arriving at the claimed species from the generic Formula I of D1/D7 required " multiple selections " among independent variables (R1–R6), and that the Controller impermissibly relied on more than one prior art document to construct a single "closest prior art" novelty attack — a submission with real doctrinal pedigree, since novelty (unlike obviousness) is ordinarily tested against a single prior document read as a whole. The Court's response — invoking AstraZeneca AB and Boehringer Ingelheim v. Vee Excel — collapses the " covered vs. disclosed " dist...
India became a member of the Madrid Protocol on July 8, 2013. At the time, the advantages of filing through the Madrid System were substantial when compared to filing a Convention or ordinary application directly in India. Initial Advantages of the Madrid Route Under the Madrid System, there was no limitation on the number of goods or services that could be listed in the specification. By contrast, applicants filing directly in India were required to pay additional fees for every character beyond 500 (excluding spaces) in the description of goods or services. Furthermore, Madrid applicants were not required to pay an association fee, whereas direct applicants with prior pending or registered applications for the same mark were liable to pay an association fee for each such prior application. Additional benefits of the Madrid route included savings on attorney fees and the convenience of centralized management of a trademark portfolio across multiple jurisdictions. Narrowing of the ...